Repression of GW/P body components and the RNAi microprocessor impacts primary ciliogenesis in human astrocytes by Joanna J Moser et al.
RESEARCH ARTICLE Open Access
Repression of GW/P body components and the
RNAi microprocessor impacts primary ciliogenesis
in human astrocytes
Joanna J Moser1, Marvin J Fritzler1 and Jerome B Rattner1,2*
Abstract
Background: In most cells, the centriolar component of the centrosome can function as a basal body supporting
the formation of a primary cilium, a non-motile sensory organelle that monitors information from the extracellular
matrix and relays stimuli into the cell via associated signaling pathways. Defects in the formation and function of
primary cilia underlie multiple human diseases and are hallmarks of malignancy. The RNA silencing pathway is
involved in the post-transcriptional silencing of > 50% of mRNA that occurs within GW/P bodies. GW/P bodies are
found throughout the cytoplasm and previously published live cell imaging data suggested that in a malignant
cell type (U2OS), two GW/P bodies reside at the centrosome during interphase. This led us to investigate if a
similar relationship exists in primary cells and if the inhibition of the miRNA pathway impairs primary cilium
formation.
Results: Two GW/P bodies as marked by GW182 and hAgo2 colocalized to the basal body of primary human
astrocytes as well as human synoviocytes during interphase and specifically with the distal end of the basal body
in the pericentriolar region. Since it is technically challenging to examine the two centrosomal GW/P bodies in
isolation, we investigated the potential relationship between the global population of GW/P bodies and primary
ciliogenesis. Astrocytes were transfected with siRNA directed to GW182 and hAgo2 and unlike control astrocytes, a
primary cilium was no longer associated with the centrosome as detected in indirect immunofluorescence assays.
Ultrastructural analysis of siRNA transfected astrocytes revealed that knock down of GW182, hAgo2, Drosha and
DGCR8 mRNA did not affect the appearance of the earliest stage of ciliogenesis but did prevent the formation and
elongation of the ciliary axoneme.
Conclusions: This study confirms and extends a previously published report that GW/P bodies reside at the
centrosome in U2OS cells and documents that GW/P bodies are resident at the centrosome in diverse non-
malignant cells. Further, our study demonstrates that repression of key effector proteins in the post-transcriptional
miRNA pathway impairs primary cilium formation.
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Background
In most eukaryotic cells the centrosome, composed of
centrioles and associated pericentriolar material (PCM),
acts as a major microtubule organizing center (MTOC)
participating in the organization of both the interphase
cytoskeleton and the mitotic spindle. In addition, the
centriole component of the centrosome can function as a
basal body that organizes the formation of a cilium while
in many cases the associated PCM continues to operate
as a cytoplasmic MTOC. This cilium can be one of two
types, a motile cilium with a 9+2 arrangement of microtu-
bules or non-motile (primary) cilia with 9+0 arrangement
of microtubules (reviewed in [1]). Most vertebrate cells
contain a single non-motile primary cilium that is
assembled in a step-wise manner from the distal end of
a mature centriole within the centrosome. We have
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previously shown that primary ciliogenesis in cultured
human astrocytes and synoviocytes proceeds through
stages beginning with the formation of a membrane
bound vesicle at the distal end of the basal body (here
referred to as stage 1) followed by the establishment and
growth of a 9+0 ciliary axoneme [2,3]. Although long
ignored, the primary cilium has recently been the focus of
intense investigation. These efforts have established that
the primary cilium is a key coordinator for a variety of sig-
naling pathways that function in development and tissue
homeostasis. Importantly, defects associated with the pri-
mary cilium underlie a variety of human diseases and
developmental disorders including Alström, Bardet-Biedl,
Joubert, Meckel-Gruber and Oral-facial-digital type 1 syn-
dromes where common clinical phenotypes include obe-
sity, ataxia and mental retardation, suggesting that primary
cilia are required for the proper development and particu-
larly function in the brain [4].
Proteins involved in cell cycle progression are also
linked to primary cilium expression (for review see [5-7])
and may play a role in tumor formation as reported in
two recent studies [8,9]. Further, defects in early stages of
ciliogenesis were reported as a common feature in astro-
cytoma/glioblastoma cells including highly malignant
T98G glioblastoma multiforme cells which expressed
abnormally long centrioles and no primary cilia as evi-
denced by ultrastructure analysis [2]. To date, numerous
cilia or basal body-associated proteins have been discov-
ered by proteomic, comparative genomic and bioinfor-
matic studies, representing the so-called “ciliome”
[10,11]. A recent functional genomics screen has identi-
fied potential modulators of ciliogenesis in telomerase-
immortalized human retinal pigmented epithelial cells,
however the molecules and/or pathways that regulate
ciliogenesis remain to be identified.
Centrioles/basal bodies and the primary cilium region
are associated with a variety of cellular organelles (e.g.
Golgi apparatus, nucleus) and endocytosis signaling path-
ways in a cell cycle specific manner, which frequently is
dependent upon a functional interdependence between
the centrosome/basal body and these organelles [2,3,12].
Recently, a real time microscopy study by Aizer et al.
documented that a pair of stationary GW/P bodies reside
at the centrosome in human U2OS (osteosarcoma) inter-
phase cells, a feature that is markedly different from the
majority of cytoplasmic GW/P bodies that are mobile
and can transit rapidly along microtubule tracks to and
from the centrosome [13].
GW/P bodies are cytoplasmic ribonucleoprotein gran-
ules that contain messenger RNA (mRNA), microRNA
(miRNA) and proteins involved in mRNA transport, sta-
bilization, silencing and/or degradation (reviewed in
[14,15]). Key GW/P body constituent proteins, GW182
and hAgo2, are cytoplasmic effector proteins of the RNA
silencing pathway that bind miRNA to silence and
degrade mRNA [16-18]. The observation by Aizer et al.
that two stationary GW/P bodies reside at the centro-
some in human malignant cells [13] raises the possibility
that miRNA could potentially be located at the centro-
some in GW/P bodies and may play a role in posttran-
scriptional regulation of mRNA involved in centrosome
functions including primary ciliogenesis. The idea that
RNA may be present at the centrosome is not entirely
new and is consistent with reports showing that RNA is a
component of the centrosome in the mollusc Ilyanassa
obsoleta and in the surf clam (Spisula solidissima)
[19-21] which leads us to hypothesize that GW/P bodies
and the miRNA pathway may play a yet-to-be-deter-
mined role in centrosome function such as the expres-
sion of a primary cilium. The goal of this study was to
determine if stationary GW/P bodies are also present at
the centrosome of non-malignant cells particularly those
capable of expressing a primary cilium and to determine
if the inhibition of the miRNA pathway impairs cilium
formation.
Results and Discussion
Two GW/P bodies localize to the centrosome/basal body
in cultured human astrocytes and synoviocytes
In a previous study we investigated the expression of pri-
mary cilia in both normal primary astrocytes and human
synoviocytes [2]. These studies demonstrated that in
both cell types ciliogenesis is characterized by a series of
morphological stages including an early stage during
which the basal body is associated with a vesicle at the
distal end (Stage 1) and subsequent stages (Stages 2-5)
that show various degrees of ciliary axoneme develop-
ment [2]. Unlike kidney primary cilia where the mature
axoneme extends completely free of the plasma mem-
brane, the proximal portion of the primary cilium in
these two cell types is contained within a membrane
channel contiguous with the plasma membrane (termed
the “cilium-pit”) that is integrated with the centrosome/
basal body region via microtubules, is associated with
Golgi complexes and is a major site of endocytosis [2,3].
To confirm and extend the report by Aizer et al. [13]
we examined the position of GW/P bodies relative to
the centrosome in interphase primary human astrocytes
and synoviocytes. Since results were identical for both
astrocytes and synoviocytes, here we only report the
data obtained from the primary human astrocytes. Indir-
ect immunofluorescence (IIF) analysis in over 100 inter-
phase cells showed that, in addition to abundant GW/P
bodies in the cytoplasm, GW/P body foci localize to the
centrosome in 100% of cells that were maintained in a
log phase culture, a frequency that is consistent with
GW/P bodies being components of the centrosome [13].
Figure 1A illustrates the colocalization of GW/P bodies
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Figure 1 RNA silencing proteins, GW182 and hAgo2, localize to the centrosome/basal body in human astrocytes throughout
interphase. (A) Astrocytes double labeled with mouse anti-acetylated tubulin (red) and human GW182 antiserum 18033 (green) and
counterstained with DAPI (blue). Left panel illustrates two daughter cells. Cells were seeded at a low density to allow the identification of
daughter cells following the completion of mitosis (early G1). Each cell contains a centrosome with associated GW/P bodies (arrows). Centre
panel illustrates a cell in G1/S phase (the period of primary cilium expression). One of the two GW/P bodies is demonstrated in this focal plane
at the basal body (arrow). Right panel illustrates a late S/G2 cell with prominent chromatin condensation (DAPI) and a centrosome with two
GW/P bodies (arrow). (B) GW182 and (C) hAgo2 localization to the centrosome and the basal body of primary cilia was examined by IIF using
18033 and mouse monoclonal 4F9 to recombinant hAgo2 [29] (green). Nuclei were marked by DAPI. The inset box in (B) shows the location of
GW182 marked by mouse monoclonal 4B6 antibody and (C) hAgo2 mouse monoclonal antibody relative to the primary cilia. All IIF scale bars =
15 μm. (D) GW182 localizes to the pericentriolar region in immunoelectron micrographs. Arrows indicate the immunogold stained GW/P body
foci. EM scale bars = 100 nm.
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with the centrosome in daughter cells in early G1 phase,
a late G1/S phase cell expressing a primary cilium and a
late S/G2 cell displaying prominent chromatin conden-
sation. Figure 1B shows in greater detail two GW/P
bodies positioned at the centrosome and at the basal
body during the expression of a primary cilium. These
two foci were also highlighted by mouse monoclonal
antibodies to the GW/P body component hAgo2 (Figure
1C and enlarged inset). Interestingly, hAgo2 also loca-
lized to the proximal portion of the shaft of the primary
cilium (Figure 1C and inset). These IIF experiments
were replicated using anti-glutamylated (glu) tubulin as
an alternate marker of primary cilia (data not shown). It
is important to note that a large number of GW/P
bodies (up to ~50 per cell) are characteristic of primary
human astrocytes (Moser JJ, unpublished data). The
number of GW/P bodies observed in these cells differs
greatly from those in malignant cells (astrocytoma/glio-
blastoma cell line, HeLa, HEK, U2OS) and seemingly
correlates with their extensive cytoplasmic area. Further,
the number of GW/P bodies elicited by IIF staining did
not differ when GW/P bodies are over-expressed using
GW182 GFP-cDNA (Moser JJ, unpublished data).
Immunogold electron microscopy confirmed that GW/P
body foci, as marked by prototype GW182 human anti-
serum 18033, localized to the centrosome and further clar-
ified that they are commonly found at the distal end of the
centriole in the pericentriolar region as shown in longitu-
dinal and transverse sections (Figure 1D, arrows). Taken
together with previously published reports [13], these data
suggest that two GW/P bodies are constitutive compo-
nents of the centrosome during interphase including peri-
ods of primary cilium expression.
Repression of GW182, hAgo2, Drosha and DGCR8 with
siRNA inhibits the formation of mature primary cilia in
human astrocytes
We next investigated the effect of the inhibition of the
miRNA pathway on cilia formation targeting the general
GW/P body population since it is technically challenging
to specifically target the two centrosomal GW/P bodies.
Human astrocytes were transfected with 100 nM of siRNA
directed to GW182 and hAgo2 as well as scrambled non-
targeting siRNA and Lipofectamine only (no siRNA) for
30 and 70 hours. Non-treated control and siRNA-treated
astrocytes were fixed and examined by IIF for primary
cilia expression using antibodies directed against glu tubu-
lin (Figure 2A). The specificity of the knockdown was
monitored using mouse monoclonal 4B6 to GW182 (for
si-GW182 conditions only) and mouse monoclonal 4F9 to
hAgo2 (for si-hAgo2 conditions only) (Figure 2A). In the
no siRNA/Lipofectamine only and si-scrambled treatment
conditions, mature primary cilia were observed (white)
with two GW/P body foci as marked by GW182 (green)
localized to the basal body (arrows) (Figure 2A). After
treatment with GW182 siRNA, two centrioles per cell
were still visible by conventional microscopy as marked by
anti-glu tubulin, however primary cilia were completely
absent (Figure 2A). Similarly, primary cilia were absent
and only two centrioles per cell were visible as marked by
anti-glu tubulin when astrocytes were treated with si-
hAgo2 (Figure 2A). The si-GW182 and si-hAgo2 trans-
fected cells knocked down the expression of GW/P bodies
and no green foci were present when stained using
GW182 or hAgo2 mouse monoclonal antibodies by IIF
(Figure 2A). These experiments were performed in tripli-
cate and > 250 cells were counted for primary cilia expres-
sion under no treatment control, scrambled, no siRNA/
Lipofectamine only, si-GW182 and si-hAgo2 conditions
(Figure 2B). Quantitation of primary cilia examined by IIF
showed that ~18% of control astrocytes displayed a mature
cilium and under si-scrambled and no siRNA/Lipofecta-
mine only conditions, 16% and 17% of cells displayed a
mature cilium respectively (Figure 2B). By comparison, 0%
of the cells displayed a mature cilium when treated
with siRNA to repress GW182 or hAgo2 expression at
30 hours (Figure 2B) and 70 hours (data not shown) post
transfection. Our results show that when GW/P bodies,
including centrosome/basal body GW/P bodies, were
repressed by cognate siRNA to GW182 and hAgo2, pri-
mary cilium formation was impacted.
To further examine the effect of our experimental
manipulation, an electron microscopic (EM) study was
undertaken, which showed that control astrocytes had a
centrosome/basal body -primary cilium with a morphology
similar to that previously reported (compare Figure 2C
with the results reported in Figure 3 from [2]). However,
after repression of GW182 and hAgo2 by cognate siRNA,
cells expressing a mature primary cilium were no longer
detected although basal bodies displaying a morphology
characteristic with the earliest stage of ciliogenesis (Stage
1) were observed (Figure 2C, siGW182 and si-hAgo2
panels) indicating that the inhibition of the miRNA path-
way impairs primary ciliogenesis at a specific point in its
morphogenesis.
The truncation of ciliogenesis following the disruption
of GW/P body components led us to question whether
the expression of upstream nuclear components of the
RNA silencing pathway such as the microprocessor pro-
teins Drosha and DGCR8 would also affect ciliogenesis
and thus support our initial observations. Both light and
electron microscopic analysis of primary astrocytes trea-
ted with Drosha and DGCR8 siRNA showed similar
phenotypes to that observed with GW182 and hAgo2
knockdown experiments (Figure 2C, light microscopy
data not shown). Western blot analysis confirmed that
the expression of GW182, hAgo2, Drosha and DGCR8
proteins were repressed after treatment with 100 nM of
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Figure 2 SiRNA knockdown of RNAi components, GW182, hAgo2, Drosha and DGCR8, inhibits ciliogenesis in human astrocytes. (A) The
primary cilium was examined by IIF using antibodies to glu tubulin (white) in astrocytes transfected with no siRNA/Lipofectamine, scrambled
siRNA and si-GW182 and double stained for GW bodies using mouse monoclonal 4B6 antibody to GW182 (green). The primary cilium as marked
by glu-tubulin (white) was also examined in astrocytes transfected with si-hAgo2 and double stained with mouse monoclonal 4F9 antibody to
hAgo2 (green). Nuclei were stained by DAPI. The merge + DAPI images were enlarged to focus on the cilium and centrioles relative to GW182
and hAgo2 staining. Scale bar = 15 μm. (B) The percentage of astrocytes containing primary cilia were quantitated from 5 independent IIF
experiments containing > 250 cells described in (A). Bars represent the standard deviation of the mean. (C) Ultrastructural analysis of control
astrocytes, scale bar = 400 nm, si-GW182, si-hAgo2, si-Drosha and si-DGCR8 treated astrocytes scale bars = 500 nm. (D) Human astrocytes were
transfected for 30 hours with 100 nM siRNA and Lipofectamine 2000 (Invitrogen), lysed and processed for western blot analysis. The cells in the
no siRNA/Lipofectamine lane were treated with Lipofectamine 2000 only (no siRNA) and the control lane represented untreated cells. (E) Cell
cycle analysis showing the percentage of human astrocyte cells in G1, S and G2 phase during normal growth conditions (control) and under 100
nM siRNA transfected conditions.
Moser et al. BMC Cell Biology 2011, 12:37
http://www.biomedcentral.com/1471-2121/12/37
Page 5 of 9
their respective cognate siRNAs for 30 hours (Figure
2D). The hAgo2 protein levels were decreased by ~60-
70% after treatment with si-hAgo2 whereas GW182,
Drosha and DGCR8 protein levels were decreased by
~85-95% after treatment with their cognate siRNAs
(Figure 2D). Western blot analysis of the scrambled
non-targeting siRNA/Lipofectamine only and no treat-
ment control lysates showed that the siRNA repressive
effects were specific (Figure 2D). Western blotting with
anti-actin demonstrated that equal amounts of protein
(40 μg) were loaded in each treatment condition (Figure
2D). The western blot analysis was repeated after
70 hours transfection with results identical to 30 hours
transfection (data not shown). Taken together, the
western blot results show that the cognate siRNAs for
GW182, hAgo2, Drosha and DGCR8 knocked down the
expression of their intended target with considerable
efficiency and had no observable off-target repressive
effects. The western blot data confirms our IIF results.
Finally, since ciliogenesis is tightly correlated with cell
cycle progression and primary cilia are expressed predo-
minantly during late G1/S, we performed a series of
experiments to investigate the possibility that siRNA
transfection was disrupting the cell cycle and hence
ciliogenesis. Primary human astrocytes under control
and siRNA transfection conditions were fixed and exam-
ined by flow cytometry following the addition of propi-
dium iodide (Figure 2E). Astrocytes with no siRNA
treatment and no siRNA/Lipofectamine had 88% and
83% of the cells in the G1 phase of the cell cycle,
respectively (Figure 2E). Similarly, astrocytes treated
with scrambled non-targeting siRNA had 77% of cells in
G1 phase (Figure 2E). Astrocytes treated with siRNAs to
GW182, hAgo2, Drosha and DGCR8 had 78%, 71%, 73%
and 73% of the cells in the G1 phase respectively (Figure
2E), which was similar to results obtained from control
samples. The results at 30 hours transfection were the
same after 70 hours transfection (data not shown).
These observations indicate that siRNA transfection
does not change the cell cycle profile of human astro-
cytes to an extent that would elicit a decrease in pri-
mary cilia expression or impact the interpretation of our
transfection data.
One drawback of our study is that current techniques do
not allow us to specifically target the two GW/P bodies
that reside at the centrosome and targeting the general
GW/P body population with its possible secondary effects
makes it difficult to draw a clear direct functional link
between centrosomal GW/P bodies and centrosome func-
tions such as cilium formation. We are currently attempt-
ing to address this issue using alternative experimental
approaches. We examined GW/P body specific miRNA
normalized to total cellular miRNA in human astrocytes
and found that ten different miRNAs were differentially
expressed in GW/P bodies as compared to the total cellu-
lar miRNA fraction and are predicted using Ingenuity
Pathway Analysis software (IPA) to regulate mRNA
involved in primary ciliogenesis. Six miRNA RNA-immu-
noprecipitated in GW/P bodies were predicted to regulate
KIF3A (kinesin family member 3A) and include miR-29,
miR-199, miR-181, miR-455, miR-155 and miR-145.
Three miRNA RNA-immunoprecipitated in GW/P bodies
were predicted to regulate VHL (von Hippel-Lindau
tumor suppressor) and include miR-320, miR-368 and
miR-143 and one miRNA RNA-immunoprecipitated in
GW/P bodies was predicted to regulate ODF2 (outer
dense fiber of sperm tails 2), KIF3Aand VHL and include
miR-154. All three of these mRNA are involved in the for-
mation and assembly of primary cilia [22-27]. Our preli-
minary results indicate that GW/P bodies contain miRNA
that could potentially regulate mRNA critical for primary
ciliogenesis (Moser JJ and Fritzler MJ, unpublished obser-
vations) thus raising the possibility that centrosome GW/P
bodies are required for centrosome/basal body functions,
opening a new area of investigation.
Conclusions
The real time imaging results of Aizer et al. [13] indicated
that a population of GW/P bodies were resident at the
centrosome of U2OS cells. This observation raised the
question as to whether this relationship is also found in
other cell types and if so if the inhibition of the miRNA
pathway impairs centrosome based functions. Our study
confirms and extends the observation of Aizer and co-
workers indicating that there is a population of centro-
some based GW/P bodies in diverse non-malignant cell
types. Further, we document that the inhibition of the
miRNA pathway impairs ciliogenesis halting it at a stage
prior to the initiation of axoneme formation.
Methods
Cells
Primary human cerebral cortex astrocyte cells (ScienCell
Research Laboratories, Carlsbad, CA) were cultured in cell
specific astrocyte medium containing 2% fetal bovine
serum, 1% astrocyte growth supplement and 1% penicillin/
streptomycin (ScienCell Research Laboratories). Cells were
used between passages 4 - 6. Synoviocytes were cultured
as previously described [3].
Indirect Immunofluorescence (IIF)
Cells were cultured on poly-L-lysine coated coverslips (BD
Falcon) for approximately 24 hours at 37°C and then fixed
in 100% ice cold methanol for 10 minutes. Cells were
blocked in 10% normal goat serum (NGS; Antibodies
Incorporated, Davis, CA) and 2% bovine serum albumin
(BSA; Sigma-Aldrich) for 30 minutes at room temperature
Moser et al. BMC Cell Biology 2011, 12:37
http://www.biomedcentral.com/1471-2121/12/37
Page 6 of 9
(RT) and incubated with primary antibodies at appropriate
working dilutions for 1 hour at RT.
Primary cilia were marked by three antibodies: rabbit
anti-adenylyl cyclase III (ACIII) antibody (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA), rabbit anti-glutamy-
lated (glu) tubulin (Chemicon, Temecula, CA) and mouse
anti-acetylated tubulin (Sigma, St. Louis, MO). Human
prototype GW182 antiserum 18033 was obtained from the
Mitogen Advanced Diagnostics Laboratory (University of
Calgary, Calgary, AB, Canada). Mouse monoclonal anti-
body 4B6 to recombinant GW182 and 4F9 to recombinant
hAgo2 were obtained and used as previously described
[28,29].
After washing with phosphate buffered saline (PBS), cells
were incubated for 1 hour in a dark chamber with the
corresponding secondary goat fluorochrome-conjugated
antibodies. Alexa Fluor (AF) 488 (green) or 568 (red) sec-
ondary antibodies were from Invitrogen. Slides were
washed in several changes of PBS, cell nuclei counter-
stained with 4’,6-diamidino-2-phenylindole (DAPI),
mounted in Vectashield (Vector Laboratories, Burlingame,
CA) and examined for IIF using a 100× objective on a
Leica DMRE microscope equipped with epifluorescence
and an Optronics camera. Appropriate IIF controls with
no primary antibody or only one primary antibody or both
secondary antibodies revealed no detectable bleed-through
between microscope filter sets.
siRNA Transfection
Lipofectamine 2000 (Invitrogen) was used for transient
siRNA (Dharmacon RNAi Technologies, Lafayette, CO)
transfection following the manufacturer’s protocol. Astro-
cytes were grown to ~60% confluence and transfected
with 100 nM siRNA. The siRNAs included: si-scrambled
(siGENOME non-targeting siRNA pool #1, D-001206-13-
20), si-GW182 (TNRC6A siGENOME siRNA, D-014107-
01), si-hAgo2 (EIF2C2 ON-TARGETplus SMARTpool,
L-004639-00-0005), si-Drosha (RNASEN ON-TARGET-
plus SMARTpool, L-016996-00-0005), si-DGCR8 (DGCR8
ON-TARGETplus SMARTpool, L-015713-00-0005). Cells
were fixed or lysed at 30 hours and 70 hours after
transfection.
Western Blot
Primary human astrocytes were cultured as outlined
above, harvested, pooled, and pelleted by centrifugation at
196 g for 5 minutes and washed several times with ice-
cold sterile PBS. The cell pellets were resuspended, mixed
in an equal pellet volume of PBS containing Complete
EDTA-Free Protease Inhibitor (Roche, Mannheim,
Germany), and then lysed by sonication in a water bath
for two 80 second bursts. Finally, the viscous lysates were
sheared by passing them through a syringe fitted with a
21G 1.5-inch needle and centrifuged in a tabletop
microfuge at 16,000 g for 10 minutes at 4°C. The superna-
tant was collected and stored at -20°C or -70°C for short
term or long term use, respectively. The amount of protein
in each sample was quantitated using a NanoVue spectro-
photometer (GE Healthcare Life Sciences, Baie d’Urfe,
QC) and 40 μg of protein was resolved in a 10% sodium
dodecyl sulphate - polyacrylamide gel, electrophoretically
transferred to nitrocellulose membranes (Bio-Rad Labora-
tories, Hercules, CA) and then processed for western blot
analysis. Nitrocellulose membranes were blocked for
1 hour in 5% DuraUse anti-spoil skim milk (SignaGen
Laboratories, Gaithersburg, MD) in PBS-T (0.05% Tween-
20) and overlayed with the primary antibody at the appro-
priate dilution for 1 hour at RT. Primary antibodies for
western blot analysis were monoclonal antibody 4B6 to
recombinant GW182 [28], monoclonal antibody 4F9 to
recombinant hAgo2 [29], goat antibodies to Drosha and
DGCR8 (Santa Cruz Biotechnology, Inc.) and rabbit anti-
body to actin (Sigma). Following washing with PBS-T for a
total of 30 minutes, membranes were overlayed with sec-
ondary horseradish peroxidase (HRP)-conjugated antibo-
dies, either goat anti-human (diluted 1:20,000; Sigma) or
goat anti-rabbit (diluted 1:20,000; Jackson ImmunoRe-
search, West Grove, PA) for 1 hour at RT. Membranes
were washed with PBS-T and subsequent identification of
bound antibody was detected using the Amersham
enhanced chemiluminescence (ECL) kit (GE Healthcare).
Reactive proteins were visualized by exposure and record-
ing on Amersham Hyperfilm ECL scientific imaging film
(GE Healthcare).
Cell Cycle Analysis
Astrocytes (1 × 106) were washed in PBS, resuspended in
500 μl PBS, fixed in 500 μl of 100% ethanol for 24 hours at
4°C, centrifuged at 200 g, washed in PBS and resuspended
in 500 μl propidium iodide staining buffer (50 μg/ml pro-
pidium iodide, 0.1% Triton X-100, 0.2 mg DNase free
RNase A in PBS) for 45 minutes at RT prior to flow cyto-
metry analysis at the University of Calgary Flow Cytometry
Lab (University of Calgary, Calgary, AB).
Immunogold Electron Microscopy
Cells were seeded into 35 mm dishes grown to confluence
as monolayers over two days, then washed in PBS and
fixed in 3% paraformaldehyde and 3% glutaraldehyde in
Millonig’s phosphate buffer for 1 hour at RT. Post-fixation
was in 2% OsO4 for 20 minutes at RT. The ultrathin
imbedded sections were placed directly onto carbon-
coated 200-mesh nickel grids. Each grid was hydrated with
distilled H2O and processed by incubating with fresh satu-
rated solution of 0.22 μm-filtered sodium metaperiodate
for 15 minutes at RT. After washing with distilled H2O,
sections were incubated with 0.1 N HCl for 10 minutes at
RT. After washing with PBS, sections were blocked in
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0.1% BSA and 5% NGS in PBS for 1 hour at RT and incu-
bated with primary antibody 18033 diluted 1:1000 in 0.1%
BSA and 1% NGS in PBS overnight at 4°C. Sections were
washed 3 times with 0.1% BSA and 1% NGS in PBS and
incubated with secondary 10 nm gold anti-human IgG (BB
International, UK) diluted 1:100 in 0.1% BSA/PBS for
45 minutes at RT. Washing was repeated 3 times with
0.1% BSA and 1% NGS in PBS, once with PBS alone for
5 minutes at RT and with distilled H2O an additional
5 times. Sections were contrasted with uranyl acetate and
lead citrate and then examined in a H-700 Hitachi elec-
tron microscope. Controls included incubation with sec-
ondary antibody alone and human serum antibodies to the
centromere (data not shown).
Electron Microscopy
Astrocytes were seeded into 35 mm dishes grown to
confluence as monolayers over two days, then washed in
PBS and fixed in 3% glutaraldehyde in Millonig’s phos-
phate buffer for 1 hour at RT. Post-fixation was in 2%
OsO4 for 20 minutes. The cells were dehydrated in
ethanol, and then infiltrated with Polybed 812 resin
(Polysciences Inc., Warrington, PA). Polymerization was
performed at 37°C for 24 hours. Silver-gray sections
were cut with an ultramicrotome (Leica) equipped with
a diamond knife, stained with uranyl acetate and lead
citrate and then examined in a H-700 Hitachi electron
microscope.
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